Sigma Institute of Pharmacy, Sigma University, Vadodara, Gujarat, India 390019
Cyclobenzaprine, a muscle relaxant commonly prescribed for muscle spasms, has been the subject of various analytical methods for its determination in pharmaceutical formulations and biological samples. This review critically evaluates the existing analytical techniques, focusing on UV, High-performance liquid chromatography (HPLC), Mass spectrometry (MS), and Liquid chromatography-tandem mass spectrometry (LC-MS/MS). The methods are assessed based on their sensitivity, specificity, accuracy, and applicability in different matrices. Recent advancements highlight the development of robust methodologies that comply with ICH guidelines, ensuring reliable quantification of cyclobenzaprine and its degradation products.
Cyclobenzaprine is a centrally acting skeletal muscle relaxant that is structurally related to tricyclic antidepressants. It received approval from the US FDA in 2007.
Mechanism of Action:
Cyclobenzaprine does not act directly on skeletal muscle or the neuromuscular junction. Still, it may exert effects on the spinal cord that contribute to its overall muscle relaxant properties. Research suggests that cyclobenzaprine reduces tonic somatic motor activity, impacting gamma (γ) and alpha (α) motor systems.
It effectively alleviates muscle spasms, decreases localized pain and tenderness, and enhances the range of motion in acute, painful musculoskeletal conditions.[1,2]
Introduction To Disease Muscle Spasm
Muscle spasms, often known as muscle cramps, are involuntary contractions that can occur in various parts of the body. They typically arise suddenly, cause pain, and usually resolve on their own. [4]
Muscle spasms can be categorized into two primary types:
CAUSES:
Overuse and Fatigue, Dehydration and Electrolyte Imbalance, Neurological Disorders, and Metabolic Disorders [3]
PATHOPHYSIOLOGY
SYMPTOMS
Muscle spasms typically present with[2,3]
TREATMENT
Stretching and Massage, Hydration, and Electrolyte Replacement, Medications, and Physical Therapy [4]
INTRODUCTION OF ANALYTICAL METHOD DEVELOPMENT
Analysis is vital for all products and services, but it holds particular significance for pharmaceuticals due to their impact on health. Analytical chemistry focuses on the separation, quantification, and identification of chemical components in both herbal and synthetic materials containing one or more compounds.
This field is primarily divided into two categories: qualitative analysis, which identifies the chemical constituents present in a sample, and quantitative analysis, which measures the amount of a specific compound within that sample.
The number of drugs entering the market increases each year.
In drug evaluation, the emphasis is on the identification, classification, and resolution of drugs in various forms, such as dosage forms and biological fluids.[17,18]
During the production process and drug development, analytical methods aim to provide information on efficacy, impurities, bioavailability, stability, and the effects of manufacturing variables, ensuring consistent drug product production.[10]
Fig.1 Different Types of Analytical Method[6]
PURPOSE OF ANALYTICAL METHOD DEVELOPMENT
The main objective of analytical method development is to determine the identity, purity, physical characteristics, and potency of drugs, including their bioavailability and stability.
Analytical method development and validation involves validating that analytical procedures are suitable for evaluating pharmaceuticals, particularly the active pharmaceutical ingredient (API).
Analytical techniques are designed to assess specific properties of substances against established acceptance criteria.
Therefore, analytical method development includes the careful examination and selection of the most accurate assay procedures to determine a drug's composition.[17,18]
DRUG PROFILE
|
Sr. No. |
Physiochemical Properties of Cyclobenzaprine. [2-4] |
|
|
1. |
Drug Name |
Cyclobenzaprine |
|
2. |
Molecular Structure |
|
|
3. |
Molecular Formula |
C20H21N |
|
4. |
IUPAC Name |
dimethyl(3-{tricyclo [9.4.0.0^{3,8}] pentadeca-1(15),3,5,7,9,11,13-heptaen-2-ylidene}propyl)amine |
|
5. |
Class |
Dibenzocycloheptanes |
|
6. |
Category |
Cytochrome P-450 CYP3A substrates |
|
7. |
CAS No. |
303-53-7 |
|
8. |
Molecular Weight |
275.3g/mol |
|
9. |
Official Status |
US Rx only |
|
10. |
Appearance |
White Crystalline powder |
|
11. |
Solubility |
0.00689 mg/mL |
|
12. |
Pka |
8.47 |
|
13. |
Melting Point |
217°C |
|
14. |
Partition Coefficient |
5.2 |
|
Therapeutic Properties of Cyclobenzaprine |
||
|
15. |
Uses |
Muscle Spasm, Cramps |
|
16. |
Side Effects |
Drowsiness, Dizziness |
|
17. |
Dosage and Dosage Form |
338 milligrams/kilogram in mice and 425 mg/kg in rats. |
|
Pharmacokinetics of Cyclobenzaprine |
||
|
18. |
Absorption |
The oral bioavailability of cyclobenzaprine has been estimated to be between 0.33 and 0.55. Cmax is between 5-35 ng/mL and is achieved after 4 hours (Tmax). AUC over an 8-hour dosing interval was reported to be approximately 177 ng. hr/mL. |
|
19. |
Distribution |
The volume of distribution of cyclobenzaprine is approximately 146 L. The combination of high plasma clearance despite a relatively long half-life observed with cyclobenzaprine is suggestive of extensive tissue distribution. |
|
20. |
Metabolism |
Cyclobenzaprine is extensively metabolized in the liver via both oxidative and conjugative pathways. Oxidative metabolism, mainly N-demethylation, is catalyzed primarily by CYP3A4 and CYP1A2 (with CYP2D6 implicated to a lesser extent) and is responsible for the major metabolite desmethyl cyclobenzaprine. Cyclobenzaprine also undergoes N-glucuronidation in the liver catalyzed by UGT1A4 and UGT2B10 and has been shown to undergo enterohepatic circulation. |
|
21. |
Excretion |
After administration of a radio-labeled dose of cyclobenzaprine, 38-51% of radioactivity was excreted in the urine while 14-15% was excreted in the feces. Cyclobenzaprine is highly metabolized, with only approximately 1% of this same radio-labeled dose recovered in the urine as an unchanged drug. Metabolites excreted in the urine are likely water-soluble glucuronide conjugates. |
|
22. |
Half-Life |
The effective half-life of cyclobenzaprine in young healthy subjects is approximately 18 hours. These values are extended in the elderly and those with hepatic insufficiency, with a mean effective half-life of 33.4 hours and 46.2 hours in these groups, respectively. |
|
Drug Profile of Cyclobenzaprine |
||
|
23. |
Toxicity |
The oral LD50 of cyclobenzaprine in mice and rats is 338 mg/kg and 425 mg/kg, respectively. Signs of overdose may develop rapidly after ingestion and commonly include significant drowsiness and tachycardia, with less common manifestations including tremor, agitation, ataxia, GI upset, and other CNS effects such as confusion and hallucinations. Potentially critical manifestations, though rare, include cardiac arrest or dysrhythmias, severe hypotension, seizures, and neuroleptic malignant syndrome. As the management of cyclobenzaprine overdose is complex and ever-changing, it is recommended that a poison control center be consulted before treatment. Typical management involves gastrointestinal decontamination, close cardiac monitoring, and monitoring for signs of CNS or respiratory depression. As cyclobenzaprine exists in relatively low concentrations in plasma, monitoring of drug plasma levels should not guide management and dialysis is likely of no value. |
|
24. |
Protein Binding |
Cyclobenzaprine is approximately 93% protein-bound in plasma. It has been identified as specifically having a high affinity for human serum albumin. |
LITERATURE REVIEW TABLE
Table:1 Reported UV methods for Cyclobenzaprine
|
Sr No. |
Methods |
Description |
Ref No. |
|
1 |
Simultaneous UV-Spectrophotometric Estimation of Aceclofenac and Cyclobenzaprine HCl by three different methods |
Solvent : Ethanol Detection Wavelength: 275nm for ACE and 290nm for 275nm for ACE and 290nm for CYC Linearity: 5-25µg/ml |
9 |
|
2 |
Development and Validation of Three Spectrophotometric Methods for Determination of Cyclobenzaprine HCl in The Presence of its Two Major Degradation Products |
Method A is the double devisor ratio spectra spectrophotometric method (DDR) Detection Wavelength: 216.6nm Method B is the modified ratio difference method (MRD) Detection Wavelength: 219.9nm and 278.8nm method C is mean centering of ratio spectra (MCR) Detection Wavelength: 303-377nm |
10 |
Table:2 Reported HPLC methods for Cyclobenzaprine
|
Sr No. |
Methods |
Description |
Ref No. |
|
1 |
A Validated HPLC Method using C18 Analytical Column (Agilent) for the Estimation of Cyclobenzaprine Hydrochloride by Quality by Design Approach in Bulk and Its Tablet Dosage Form |
Column: C18 column Mobile Phase: methanol: 0.01 % Orthophosphoric acid (61:39 v/v) λmax (nm): 224nm Linearity(µg/ml): 5-25µg/ml Flow rate(mL/m): 0.9 ml/min |
11 |
|
2 |
Development and Validation of RP-HPLC and UV Spectrophotometric Absorptivity Method for Simultaneous Estimation of Cyclobenzaprine hydrochloride and Aceclofenac in Pharmaceutical dosage form |
Column: C18 column (250 × 4.6 mm×5µ) (5µm particle size) Mobile Phase: e Methanol: 10mm KH2PO4 Buffer (Ph-3) (70:30 v/v) λmax (nm): 220nm Linearity(µg/ml): 3-15µg/ml for CYC and 40-200µg/ml for ACE Flow rate(mL/m): 0.9 ml/min |
12 |
|
3 |
Stability-indicating high-performance liquid chromatography and thin-layer chromatography methods for the determination of cyclobenzaprine hydrochloride and asenapine maleate |
Column: C18 column Mobile Phase: acetonitrile(0.05 m) potassium dihydrogen phosphate buffer (pH 3 ± 0.1) (70:30, v/v) λmax (nm): 290nm Linearity(µg/ml): 2.5–25 μg mL−1 Flow rate(mL/m): 1.5 ml/min |
13 |
|
4 |
Stability Indicating HPLC Method Development and Validation for the Simultaneous Estimation of Aceclofenac and Cyclobenzaprine HCl In Its Pharmaceutical Dosage Form |
Column: C18 (250mm x 4.6 mm x 2.6 µm) Mobile Phase: Buffer (pH 5.0): Methanol (60:40) v/v λmax (nm): 237nm Linearity(µg/ml): 1.5-4.5µg/ml for CYC and 20-60µg/ml for ACE Flow rate(mL/m): 1.0 ml/min |
14 |
|
5 |
Determination of Cyclobenzaprine in Tablets by High-Performance Liquid Chromatography
|
Column: C18 Mobile Phase: acetonitrile–0.6% dibasic potassium phosphate aqueous buffer (pH 3.0) (75:25 v/v) λmax (nm): 254nm Linearity(µg/ml): 0.005–0.03 mg/ml Flow rate(mL/m): 1.5 ml/min |
15 |
Table:3 Reported HPTLC methods for Cyclobenzaprine
|
Sr No. |
Title |
Method |
Ref. No. |
|
1. |
A validated inherent stability indicating HPTLC method for estimation of cyclobenzaprine hydrochloride in tablets and use of MS–QTOF in the characterization of its alkaline stress degradation product” |
Stationary Phase: Precoated silica gel 60 F 254 Mobile Phase: toluene: ethyl acetate: methanol: glacial acetic acid in the ratio 4:2:3.5:0.5 v/v/v/v. Detection:290nm Linearity(µg/ml): 200–1000 ng/band. |
16 |
CONCLUSION:
The critical review underscores the importance of reliable analytical methods for the determination of cyclobenzaprine in both pharmaceutical formulations and biological matrices. Current methodologies, particularly HPLC coupled with MS techniques, offer significant advantages in terms of sensitivity and specificity. However, challenges remain regarding the standardization and validation of these methods across different laboratories. Future research should focus on optimizing these analytical techniques further while exploring new formulations that enhance the therapeutic efficacy of cyclobenzaprine while minimizing adverse effects.
REFERENCES
Kajal Vable, Yaksh Gandhi, Khushi Prajapati, Himani Vaghasiya, Dr. Mitali Dalwadi, Dr. Chainesh Shah, Dr. Priyanka Patil, Dr. Umesh Upadhyay, Khushbu Shah, A Comprehensive and Systemic Review on the Development and Validation of Different Analytical Methods for the Estimation of Cyclobenzaprine, Int. J. of Pharm. Sci., 2025, Vol 3, Issue 9, 1683-1689. https://doi.org/10.5281/zenodo.17122482
10.5281/zenodo.17122482
